Calne man's bid to keep brother alive
9:00am Saturday 5th April 2014 in News
Businessman Marc Fitchett has set up an appeal to help his brother, Ian, who has prostate cancer and needs a life-extending drug not available on the NHS.
Mr Fitchett runs holiday company Travel Counsellors from his home in Oxford Road, Calne, and has already collected hundreds of pounds from well-wishers.
Ian, 56, who lives in Surrey, was diagnosed three years ago and has been through hormone therapy, radiotherapy and chemotherapy.
His last chemotherapy session is in April and after this there is no further treatment available on the NHS.
However, they believe the drug Enzalutamide could extend his life.
Mr Fitchett, 49, said: “On April 26 he has his last chemotherapy session and then that’s it; the NHS say they can’t do anything more for him.
“The aim is to raise money for two months’ worth of Enzalutamide, which is £5,000. He wants to prolong his life; he doesn’t want to die and he just wants to be with loved ones for as long as he can.
“He’s such a generous man. He’s always thinking about other people. He’s a dad, brother, granddad, uncle and a son, so he will really be missed by everyone.”
Before his illness, Ian ran a newsagent’s shop in Mytchett with wife Jackie. He has two daughters and four grandchildren.
Draft guidance published by the National Institute for Health and Care Excellence (NICE) say men, like Ian, who have been treated with Abiraterone do not qualify for Enzalutamide.
Mr Fitchett said: “A lot of people say it should be provided by the NHS if it’s available. He probably won’t see past Father’s Day in June without it. Just imagine if you knew that you could see someone for a certain amount of time or not at all, what would you choose? If it’s someone you hold dear most people would choose the latter.”
Any money remaining after the treatment will be donated to Men United, a campaign organised by Prostate Cancer UK.
Donations can be made online at www.gogetfunding. com/project/ian-s-lifeline-fund#/comments
Comments are closed on this article.